Halozyme Therapeutics Raises FY2026 Adj EPS Guidance from $8.65-$9.00 to $8.75-$9.05 vs $8.84 Est; Raises FY2026 Sales Guidance from $1.835B-$1.910B to $1.860B-$1.925B vs $1.879B Est
Benzinga Newsdesk 11 hours ago
NewsGuidance
Halozyme Therapeutics (NASDAQ:HALO) raises FY2026 Adj EPS guidance from $8.65-$9.00 to $8.75-$9.05 vs $8.84 analyst estimate. Raises FY2026 sales outlook from $1.835 billion-$1.910 billion to $1.860 billion-$1.925
Halozyme Therapeutics (NASDAQ:HALO) raises FY2026 Adj EPS guidance from $8.65-$9.00 to $8.75-$9.05 vs $8.84 analyst estimate. Raises FY2026 sales outlook from $1.835 billion-$1.910 billion to $1.860 billion-$1.925 billion vs $1.879 billion estimate.